Leading global pharmaceutical manufacturer, Aesica, has announced the new Site Director of its formulation development facility in Nottingham (UK).
Ian Lafferty has been promoted from his previous position as Chief Technical Officer and will oversee the continued growth of the site and the increased interest in high potency and biological formulations following the recent expansion of its high containment and sterile manufacturing suite.
Ian commented: “I plan to build on the strong foundations established by the Formulation Development team to ensure that this site plays a pivotal role in the continued growth of Aesica on a global scale. It’s an ideal time to be joining the senior management team and I relish the opportunity to drive the business forward in line with our exciting expansion plans.”
“Our success as a company is all about our people. We have some superb talent in our Formulation Development business which I plan to tap into. I’m a real believer in staff development and that’s something I’m going to champion amongst my team.”
As well as the changes in personnel, the site’s high potency suite has also been extended.
Ian, who graduated from De Montfort University, UK, with a PhD in Pharmaceuticals, added: “Our high potency facility is currently undergoing significant expansion which will strengthen our offering on the international stage. One of my key goals initially is to attract new strategic partners in the coming months based on our high containment capabilities.”
Paul Titley, Managing Director, Aesica Formulation Development, adds: “Ian’s appointment is strategically important to the business as we expand into new markets and therapeutic areas. This is a time of substantial and positive change for our business, and having the right people, like Ian, in leadership positions is absolutely critical for our long term growth.”
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.